NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leading Anti-Cancer Drugs and Associated Market 2012-2022

http://www.reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Cancer treatments - discover which products have greatest potential

Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022.

How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs.

Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of five submarkets to 2022, finding potential revenues:

Traditional antineoplastic agents

Read more here:
Leading Anti-Cancer Drugs and Associated Market 2012-2022